Can a dengue vaccine protect those with autoimmune conditions?
NCT ID NCT07087912
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 30 times
Summary
This study is testing a live attenuated dengue vaccine (Butantan-DV) in 477 people aged 12–59 with stable autoimmune rheumatic diseases (like rheumatoid arthritis or lupus) and in healthy volunteers. The goal is to see if the vaccine is safe and produces a strong immune response in these patients. Participants receive one shot and are followed for a year with blood tests and symptom diaries.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for JUVENILE IDIOPATHIC ARTHRITIS (JIA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital das Clínicas da Faculdade de Medicina da USP
RECRUITINGSão Paulo, São Paulo, 01246-903, Brazil
-
Rheumatology Division, Faculdade de Medicina da USP
RECRUITINGSão Paulo, São Paulo, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.